In this SmartTRAK interview, National Director of Sales Ben Browne shares his insights on the TendoNova device, a minimally invasive tool for treating refractory tendinopathy through soft tissue fragmentation and debridement that can also be combined with orthobiologics like platelet-rich plasma (PRP). Click on the following video to learn more (08:37 min). A link to download a transcript of the complete interview is also provided below.
SmartTRAK: Hi, this is David Shepard with SmartTRAK. I'm here with Ben Browne, national sales director for TendoNova. Ben, tell me a little bit about the product and how things are going at the booth today.
Ben Browne: So, it's a great conference, very active, most of the conference so far. And TendoNova is essentially a device that providers are going to use, perhaps instead of or in addition to orthobiologics, to treat a common refractory tendinopathy patient. A patient who's perhaps failed conservative therapies, they've dealt with tendinopathy or tendinosis for at least three months, in some cases, many months. And once again, they failed many conservative therapies. What's great about TendoNova is that ..
Click the button to get the full transcript of our exclusive interview with TendoNova's National Sales Director Ben Browne conducted by David Shepard, SmartTRAK GM/Sr Analyst, Orthobio & Regen.